Our research has resulted in several well-received key manuscripts :
- Yang L, Ravindranathan P, Hammes SR, Hsieh JT and Raj GV. Central role for PELP-1 in Non-androgenic activation of Androgen receptor in Prostate Cancer. Mol Endocrinol. 2012; 26(4):550-61. PMID:22403175.
- Details a novel critical signaling pathway involving the interaction between the androgen receptor and a key molecule PELP1 that could be important as a driver of resistance in prostate cancer.
- Further validation of the PELP1 protein in signaling has been noted in Roy et al., Mol Cancer Res. 10(1):25-33; 2012
- Additional work charactering molecular pathways in prostate cancer include paxillin (Sen et al, J Clin Invest. 122(7):2469-81, 2012 and Sen et al, J Biol Chem. 285(37):28787-95, 2010)
- Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun. 2013;4:1923. PMID: 23715282.
- This manuscript details the design, development and validation of a novel class of drugs targeting the interaction between the androgen receptor and PELP1 in prostate cancer.
- Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol. 2013. PMID 23752995.
- Details the development of a novel ex vivo methodology using primary prostate cancer tissues that maintain androgen receptor signaling and responsiveness and that can be used for personalized medicine.
- This model has also been described in several additional manuscripts, both published and in press, including Centenera et al. Clin Cancer Res. 18(13):3562-70; 2012, Schiewer et al, Cancer Discov. 2012, and Ravindranathan et al, Nat Commun. 4:1923, 2013.